Sonelokimab

DB18843InvestigationalProtein Based Therapies

Sonelokimab is under investigation in clinical trial NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa).

Mechanism: Pharmacologically active on Interleukin-17A and Interleukin-17F
Curator reviewed
Also known as: M-1095 (anti-interleukin (il)-17a/f single-domain antibody)
Code names: ALX-0761 · M-1095

Resolves to

Compound

UNIILEN0OCZ4SHCAS1414386-05-2

Targets

Q16552IL17AQ96PD4IL17F

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Sonelokimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account